Morgan Stanley analyst Aisyah Noor maintained a Hold rating on Tecan Group AG today and set a price target of CHF168.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aisyah Noor’s rating is based on a combination of factors that present both opportunities and challenges for Tecan Group AG. The company has shown positive order improvements in the third quarter compared to the second quarter, with their largest customer performing at the upper end of guidance. Additionally, the pharmaceutical sector and US activities are maintaining strong performance, which supports the company’s outlook.
However, there are concerns that have led to the Hold rating. The performance in China is not meeting expectations, and there is a delay in order fulfillment to 2026 due to tariffs affecting the Synergence segment. Moreover, the foreign exchange impact on the fiscal year’s margin is stronger than anticipated, affecting profitability. These mixed signals suggest that while there is potential for recovery, caution is warranted in the short term.
Noor covers the Healthcare sector, focusing on stocks such as Qiagen, bioMerieux, and DiaSorin S.p.A.. According to TipRanks, Noor has an average return of 6.3% and a 62.07% success rate on recommended stocks.